Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

YM BioSciences Announces Election of Dr. Kapil Dhingra

Published: Thursday, November 22, 2012
Last Updated: Thursday, November 22, 2012
Bookmark and Share
Dr. Dhingra has been elected by shareholders to the Company's Board of Directors.

YM BioSciences Inc. has announced that Kapil Dhingra has been elected by shareholders to the Company's Board of Directors at YM's Annual Meeting of Shareholders held this afternoon.

Dr. Dhingra has 25 years of experience in oncology clinical research and drug development. Previously, Dr. Dhingra held the position of Vice President, Head, Oncology Disease Biology Leadership Team at Roche, playing a key role in the expansion of Roche oncology.

He is currently the Managing Member of KAPital Consulting, a healthcare consulting firm he founded in June 2008 dedicated to assisting biotechnology, pharmaceutical and diagnostic companies realize the full potential of scientific, clinical and commercial advances in oncology.

He serves on the Board of Directors of a number of companies, including Exosome Diagnostics and Algeta.

Throughout his industry career, Dr. Dhingra maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor and more recently at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra received his medical training at the All India Institute of Medical Sciences, New Delhi, India.

"As we advance our lead drug CYT387 to the next phase in its development, it is important to continue to strengthen our board with the experience and expertise that Dr. Dhingra brings," said Mr. David Allan, Chairman of YM BioSciences.

Mr. Allan continued, "We would also like to thank Dr. Philip Frost and Dr. François Thomas for their long and valuable participation on the Board of Directors."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
Pivotal trials for CYT387 in myelofibrosis to begin in the second half of calendar 2012.
Tuesday, May 15, 2012
YM BioSciences Reports Operational and Financial Results
Company reports operational and financial results for the second quarter of fiscal 2012.
Friday, February 10, 2012
YM BioSciences Proposes Dr. Catherine Mackey and Dr. Nicole Onetto for Nomination to Board of Directors
Company announces annual and special meeting of shareholders and appoints new head of strategic alliances.
Monday, October 24, 2011
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
Enrollment of phase I/II trial for CYT387 complete.
Monday, September 26, 2011
YM Biosciences Announces Conclusion of Phase I Dose-Escalation and Expansion of Ongoing Cyt387 Phase I/II Clinical Study
CYT387 has shown significant activity in reducing spleen size and controlling symptoms in patients with myelofibrosis.
Thursday, August 12, 2010
YM BioSciences Granted Two US Patents for AeroLEF®
Additional AeroLEF patents granted in Europe, China and other territories.
Thursday, February 11, 2010
YM BioSciences and Therapure Biopharma Announce Contract
Therapure Biopharma to perform fill and finish services for nimotuzumab.
Thursday, December 24, 2009
YM BioSciences and NRC-BRI Produce New Breast Cancer Drug Candidates
Collaboration to create optimized antibodies produces first candidates which selectively target HER2 in breast cancer.
Tuesday, December 15, 2009
YM BioSciences USA Receives Clearance from US Treasury Department to Extend Clinical Program for Nimotuzumab
Company now plans for IND submissions with the FDA to include US patients in randomized, double-blinded lung cancer and brain metastases trials.
Tuesday, August 11, 2009
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!